{"id":"NCT00616421","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","officialTitle":"A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-04","completion":"2009-10","firstPosted":"2008-02-15","resultsPosted":"2011-06-09","lastUpdate":"2016-02-15"},"enrollment":2907,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":["Menveo"]},{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":["Menveo"]},{"type":"BIOLOGICAL","name":"Licensed meningococcal ACWY vaccine","otherNames":["Menactra"]}],"arms":[{"label":"MenACWY-CRM (1 dose)","type":"EXPERIMENTAL"},{"label":"Licensed polysaccharide vaccine","type":"ACTIVE_COMPARATOR"},{"label":"MenACWY-CRM (2 doses)","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.","primaryOutcome":{"measure":"Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age","timeFrame":"1 month postvaccination","effectByArm":[{"arm":"MenACWY-CRM (1 Dose)","deltaMin":72,"sd":null},{"arm":"Licensed Polysaccharide Vaccine","deltaMin":77,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":68,"countries":["United States","Canada"]},"refs":{"pmids":["20943209"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":351},"commonTop":["injection site pain","injection site erythema","injection site induration","irritablility","somnolence"]}}